Question 14013 — maternity health insurance

Summary

Mr. Quentin Bataillon draws the attention of the Minister of Health and Prevention to the delisting of medications against degenerative Lewy body disease (MCL). Léwy body disease is a complex, neuroprogressive neurocognitive pathology, with varied symptoms, affecting different areas of the brain. To date, no curative treatment exists. But, since 2018, treatments that helped relieve symptoms of the MCL are no longer reimbursed by social security. Around 200,000 individuals are affected in France, suffering from various cognitive, motor and psychological pathologies. For them, as for their families and associations, medications such as donepezil, memantine, rivastigmine and galantamine provide real relief from everyday pain. Their dereimbursement leads to double punishment for patients, who cannot do without treatments, but now have to pay a hefty bill to obtain them. This situation leads some patients to give up treatment and are forced to suffer the rapid deterioration of their pathology. Given these elements, he would like to know the Government's position regarding the reimbursement of medicines against Léwy body disease.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.